Dr. Lanny Johnson, M.D.

Lanny L. Johnson, M.D. is the founder of AntiOxidant USA Research and Development

He is an internationally recognized orthopedic surgeon. He is an inventor and holder of more than 50 US patents in medicine and surgery. He was one of the pioneers in arthroscopic surgery and as such most recognized as the inventor of the motorized instrumentation still used worldwide today in all such procedures.

In 2018 he was invited to submit the following manuscript to the Bone and Joint Journal that reflected upon his career; a short autobiographical article.

Johnson LL. What’s Important: Making a Difference May Include Being Different. J Bone Joint Surg. 2018 Mar 7; 100 (5): 443. DOI 10.2106/JBJS.18.00011.


or http://drlanny.com/physiciansurgeon/making-a-difference-may-include-being-different/

After concluding his clinical practice he has continued his interest in medical research and development. In 2005, upon learning of the effect of the dyes that give color to cherries to stimulate the rodent pancreatic cells to produce insulin, he reasoned there may be other applications. Independent studies at Scripps Institute in La Jolla, California confirmed his hypothesis that these dyes would cause the human joint lining to turn on the growth factor gene for Insulin-Like Growth Factor-1. IGF-1 has long been known to heal articular cartilage. This resulted in US patents for intraarticular injection treatment of synovial joint arthritis; i.e. knee, hip, shoulder, etc.

It was learned that the bioactive reagent was not those parent dyes found in fruits but the primary metabolite; protocatechuic acid (PCA). PCA is a phytochemical in the food supplement category. It is a nutraceutical.

Subsequent studies demonstrated that PCA increased the genetic expression of the growth hormone, Insulin-Like Growth Factor-1 (IGF-1) in cells and tissues. He also showed in animal studies that PCA in certain small concentrations of PCA optimized the local skin growth hormones to heal a wound very rapidly. PCA caused in just 2 days the increase of collagen in the skin wound. Collagen is fundamental to bone structure.


The following patents are in this portfolio as of August 31, 2021.  The specific claims of each may be view under the patent number at https://patft.uspto.gov/netahtml/PTO/srchnum.htm

September 11, 2012.  This patent showed that the dyes of plants (anthocyanins and anthocyanins) the precursor of the metabolite protocatechuic acid turned on the gene for growth hormone IGF-1 in human synovium.

November 8, 2016.  This patent secured the intra articular injection route not previously included in the granted patent claims for cyanidin-3-glucoside.

November 22, 2016.  This was the parent patent showing broad spectrum antibiotic properties and wound healing acceleration.  See the illustrations above.

March 27, 2018.This was a continuation of the parent application that adds 2,4,6 trihydroxybenzaldehyde to the broad-spectrum antibiotic, plus collagen proliferation (i.e. wrinkle treatment) and reduction in scar formation.

March 27, 2018.This was a continuation of the parent application that adds 2,4,6 trihydroxybenzaldehyde to the broad-spectrum antibiotic, plus collagen proliferation (i.e. wrinkle treatment) and reduction in scar formation.

May 15, 2018.  This patent secures that protocatechuic acid can only be manufactured and delivered to an end user by the owner of this patent.


June 5, 2018.  This patent was a continuation of 9,925,152 that now allowed for intra-articular injection.

July 26, 2018.  This patent included the metabolites of protocatechuic acid and 2,4,6 trihydroxybenzaldehyde for the destruction of biofilms of MRSA and Pseudomonas on metal, cloth and ceramic.

July 26, 2018.  This was an expansion of 10,004,705 applications.

July 10, 2018. This patent expanded the formulation for treatment of implants to include protocatechuic acid, 70% isopropyl alcohol, propylene glycol, and an essential oil.

July 31, 2018. This patent includes the chemical formulation of 10,016,380 for medical and surgical implants, dental implants and instrumentation.  The later for spaying or soaking in solution.

December 4, 2018. This patent secures the use of PCA to  coat a bandage or dressing at time or treatment and or a commercial preparation for as stated in claim #22 if a wound is a burn, skin break, bone break, muscle tear, puncture, surgical incision site, microdermabrasion site, skin graft site, a wound associated with diabetes, a bed sore, a pressure sore, skin defoliation, or a laceration, and wherein the protocatechuic acid becomes activated by contact with moisture from the wound.

April 23, 2019. An extension of prior claims that specifically cite PCA as an antibacterial for Propionibacterium acnes.  This for the treatment of skin acne.

May 21, 2019.   This patent extends the use of PCA to the food industry.

September 3, 2019. This is a non-surgical method of loosening biofilms from an implant via ultrasound and then treating without surgery.  The treatment would be repeated needle aspirations for infection status and then injection of protocatechuic acid crystals to destroy the biofilms attached to the implant.

October 1, 2019. This is an extension and further specification of the skin penetration formulation claims for pre-operative skin disinfection and facial acne with concentration above 10%.

September 5, 2020.  This is an extension that includes the disinfectant and sanitizer use emphasizing the residual anti-microbial protocatechuic acid coating the remains on the article and or person after the evaporation of the liquid vehicle.


March 30, 2021.  The treatment of COVID19 virus with protocatechuic acid.  This patent is for treating the patient; oral, intravenous, injection, etc.  Working toward regulations approvals.

August 31, 2021.  Anti-microbials and the Methods and Use thereof. This patent is for mitigation of bacteria and virus (COVID 19) by coating of personal protective equipment; masks, gowns, hats, shoes, etc.

Studies were then advance to examine the effects of PCA on osteoarthritis. The results showed that PCA caused the human and mammal joint lining to produce the growth hormone IGF-1 and cause the modification of osteoarthritis progression in the experimental animal.

He reasoned that if PCA resulted in growth hormone production locally would it be possible that PCA could stimulate human bone cells to produce bone. The answer was yes and the foundation of a US patent is pending. Effect on Bone Cells

The scientists involved in study number one were surprised at the findings and advised that a study should be performed to learn if PCA would cause human MSC to convert to bone-producing osteoblasts. The answer was yes. Effect on Stem Cells

This basic science evidence suggests that PCA would help support healthy bone and teeth.

These research findings provide the foundation to advance animal studies examining the potential for enhancing fracture healing and bone grafting procedures.